Team Inc
Change company Symbol lookup
Select an option...
TISI Team Inc
PRTK Paratek Pharmaceuticals Inc
KIRY Kiewit Royalty Trust
OCAXW OCA Acquisition Equity Warrant Exp 14 Jan 2026 *W EXP 01/31/2028
ABBV Abbvie Inc
IIIN Insteel Industries Inc
KO Coca-Cola Co
MOD Modine Manufacturing Co
WABC Westamerica Bancorp
LUV Southwest Airlines Co
Go

Industrials : Commercial Services & Supplies | Small Cap Value
Company profile

Team, Inc. is a provider of integrated, digitally-enabled asset performance assurance and optimization solutions. The Company’s segments include Inspection and Heat Treating (IHT), Mechanical Services (MS) and Quest Integrity. IHT segments provides conventional and advanced non-destructive testing services primarily for the process, pipeline and power sectors, pipeline integrity management services, and field heat treating services, as well as associated engineering and condition assessment services. MS provides solutions designed to serve both the operational (onstream) and off-line states of their assets. Its onstream service offers a range of standard to custom-engineered leak repair and composite solutions, emissions control and compliance, hot tapping and line stopping and on-line valve insertion solutions. Quest Integrity provides integrity and reliability management solutions for the process, pipeline and power sectors.

Closing Price
$1.34
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
0

10-day average volume:
517,378
0

Longeveron stock rockets on very heavy volume after upbeat FDA news

10:57 am ET November 18, 2021 (MarketWatch)
Print

Shares of Longeveron Inc. (LGVN) blasted 120.9% higher on very active morning trading Thursday, after the biotechnology company said its Lomecel-B for the treatment of a congenital heart defect in infants (Hypoplastic Left Heart Syndrome) affecting about 1,000 babies a year was granted rare pediatric disease (RPD) designation by the Food and Drug Administration. Trading volume exploded to 112.0 million shares, compared with the full-day average of about 110,000 shares. The stock was both the biggest gainer and most active on major U.S. exchanges. The company said Lomecel-B is currently being evaluated in a Phase 2 trial. Despite the rally, the stock, which went public in February, was still trading well below the initial public offering price of $10 a share. The stock has now climbed 77.7% over the past three months, while the iShares Nasdaq Biotechnology ETF (IBB) has slipped 8.8% and the S&P 500 has gained 6.4%.

-Tomi Kilgore

	

(END) Dow Jones Newswires

November 18, 2021 10:57 ET (15:57 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.